Venture Affairs Of The Heart
This article was originally published in Start Up
A survey of the fundraising activities of 183 private cardiovascular medtech, biopharma, and diagnostics companies from 2010 through April 2015 revealed that by 2014, following two years of waning venture investments, the group had raised less than half the capital secured in 2010. And although the average raised per round was roughly the same, the volume of deals was significantly higher in 2010.
You may also be interested in...
Start-Up surveyed investments into, and exits by, private infectious disease-focused companies from 2013 through the first quarter of 2016, using data from Informa’s Pharma Intelligence's Strategic Transactions and Medtrack databases. Our review reveals an increasing amount of money going into these firms, especially those developing novel antibiotics against drug-resistant bacteria or with novel anti-infective drug development platforms.
Investments in endocrine/metabolic disease-focused medtech companies reached a four-year high in 2015. Biopharma companies grabbed the majority of the funds that have been raised since 2012, and among medtechs, those focused on diabetes fared best.
Medtech M&A activity has been on the rise for several years along with a surge in the number of higher-valued mega-deals, those worth at least $1 billion. Yet a survey of all deals with known values indicates that median deal value has actually declined.